Form 4: Incyte Director Edmund Harrigan Reports Stock Transactions

Director Edmund Harrigan of Incyte Corp. reports acquiring 339 shares and holding 17,071 shares of common stock, including unvested restricted stock units.

Summary

• Edmund Harrigan, a director at Incyte Corp., reported a transaction involving the company's common stock.
• On December 31, 2024, Mr. Harrigan acquired 339 shares of common stock at a price of $69.07 per share.
• These shares were received as restricted stock in lieu of quarterly director retainer fees.
• The restricted shares are fully vested.
• Following the transaction, Mr. Harrigan beneficially owns 17,071 shares of Incyte common stock.
• This total includes 2,830 shares issuable from previously reported restricted stock units that have not yet vested.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction by a director, which is generally neutral to positive. The use of a pre-arranged plan adds a layer of transparency.

Positives

• The acquisition of shares by a director can be seen as a positive sign of confidence in the company.
• The use of a pre-arranged plan suggests a structured and transparent approach to stock transactions.

Industry Context

This is a routine filing related to insider transactions and is common for publicly traded companies. It does not indicate any specific trend in the pharmaceutical industry.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, and this filing is consistent with those requirements.
• The transaction is a common method of compensation for directors, using restricted stock in lieu of cash fees.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it shows director confidence in the company.

Key Dates

Keywords

Incyte, Director, Stock Transaction, Beneficial Ownership, Restricted Stock, Form 4, Edmund Harrigan